SCHEMBL4759622

SCHEMBL4759622

CC(C)CCCC(C)CCCC(C)CCCC(C)CCN(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
BLM P54132 1/20 0.40
SIGMAR1 Q99720 2/20 0.40
KDM4E B2RXH2 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 1/20 0.39
APOBEC3A P31941 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
KCNH2 Q12809 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
AOC3 Q16853 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28852361 0.87 LMNA (0.50) LMNABLMSIGMAR1KDM4EL3MBTL1
SCHEMBL87643 0.86 SIGMAR1 (0.46) SIGMAR1KDM4EL3MBTL1POLBAPOBEC3A
SCHEMBL15423270 0.85 SIGMAR1 (0.45) SIGMAR1KDM4EL3MBTL1POLBAPOBEC3A
SCHEMBL4761360 0.83 TSHR (0.43) LMNABLMSIGMAR1KCNH2MEN1
SCHEMBL23758991 0.81 LMNA (0.33) LMNABLMKDM4EL3MBTL1POLB
SCHEMBL15301724 0.77 BCHE (0.43) LMNASIGMAR1KCNH2MEN1KMT2A
SCHEMBL4649083 0.77 TDP1 (0.46) SIGMAR1KDM4EL3MBTL1POLBAPOBEC3A
SCHEMBL92732 0.73 POLB (0.52) LMNAKDM4EL3MBTL1POLBAPOBEC3A
SCHEMBL13005300 0.73 HTR2A (0.46) SIGMAR1KDM4EL3MBTL1KMT2AALDH1A1
SCHEMBL5668643 0.73 LMNA (0.50) LMNABLMPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101404985-A Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB PUBL (SE) 2009-04-08 CN disclosed
EP-2004159-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS Biovitrum AB (publ) (SE) 2008-12-24 EP disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 US disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 US disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 WO disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects CYBB, NOX1, NOX5 LMNA 4180/4885BLM 2996/4885SIGMAR1 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.